Hormone | Number of cases/Number of controls | Unadjusted | Adjusted | ||||
---|---|---|---|---|---|---|---|
 |  | OR | (95% CI) | P b | OR | (95% CI) | P b |
All participants | Â | Â | Â | Â | Â | Â | Â |
Testosterone | Â | Â | Â | 0.005 | Â | Â | 0.006 |
   9.4-20.0 ng/dl | 17/49 | 1.0 |  |  | 1.0 |  |  |
   20.1-26.9 ng/dl | 27/40 | 1.9 | (0.9 to 4.2) |  | 2.1 | (0.9 to 4.8) |  |
   27.0-34.3 ng/dl | 22/45 | 1.3 | (0.6 to 2.9) |  | 1.5 | (0.6 to 3.4) |  |
   34.4-65.5 ng/dl | 32/34 | 2.9 | (1.4 to 6.3) |  | 3.3 | (1.5 to 7.5) |  |
Bioavailable testosterone | Â | Â | Â | 0.002 | Â | Â | 0.002 |
   3.0-8.0 ng/dl | 19/46 | 1.0 |  |  | 1.0 |  |  |
   8.1-10.8 ng/dl | 21/46 | 1.4 | (0.6 to 3.1) |  | 1.7 | (0.7 to 4.2) |  |
   10.9-13.8 ng/dl | 24/45 | 1.4 | (0.6 to 3.0) |  | 1.7 | (0.7 to 4.0) |  |
   14.0-30.4 ng/dl | 34/31 | 3.2 | (1.4 to 7.1) |  | 4.2 | (1.6 to 10.9) |  |
SHBG | Â | Â | Â | 0.34 | Â | Â | 0.48 |
   11.3-42.2 nmol/L | 25/41 | 1.0 |  |  | 1.0 |  |  |
   42.5-57.9 nmol/L | 27/40 | 1.0 | (0.5 to 2.0) |  | 1.3 | (0.6 to 2.8) |  |
   58.3-77.6 nmol/L | 25/42 | 0.9 | (0.5 to 1.9) |  | 1.1 | (0.5 to 2.8) |  |
   78.1-198.0 nmol/L | 21/45 | 0.7 | (0.3 to 1.5) |  | 0.8 | (0.3 to 2.0) |  |